Browsing by Author "Naber, CK"
Now showing items 1-5 of 5
-
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu, B; Saito, Y; Baumbach, A; Kelbaek, H; van Royen, N; Zheng, M; Morel, M-A; Knaapen, P; Slagboom, T; Johnson, TW (2019-09-09) -
Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Chieffo, A; Tarantini, G; Naber, CK; Barbato, E; Roffi, M; Stefanini, GG; Buchanan, GL; Buszman, P; Moreno, R; Zawiślak, B (2021-02-19)The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of ... -
Predicted clinical and economic burden associated with reduction in access to acute coronary interventional care during the COVID-19 lockdown in two European countries
Lunardi, M; Mamas, MA; Mauri, J; Molina, CM; Rodriguez-Leor, O; Eggington, S; Pietzsch, JB; Papo, NL; Walleser-Autiero, S; Baumbach, A (2023) -
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
Lansky, A; Wijns, W; Xu, B; Kelbæk, H; van Royen, N; Zheng, M; Morel, M-A; Knaapen, P; Slagboom, T; Johnson, TW (Elsevier, 2018-09-29)Summary Background The FIREHAWK is a drug-eluting stent with a fully biodegradable sirolimus-containing polymer coating localised to recessed abluminal grooves on the stent surface. We investigated clinical outcomes with ... -
Validation of the all-comers design: Results of the TARGET-AC substudy.
G Toth, G; Lansky, A; Baumbach, A; Kelbæk, H; van Royen, N; Holmvang, L; Janssens, L; Brugaletta, S; Barbato, E; Maillard, L (2020-03)BACKGROUND: Results of clinical trials are often criticized by low inclusion rate and potential sampling bias in patient recruitment. The aim of this validation registry is to evaluate how far an all-comers design in the ...